Article

Long-term results after resection for soft tissue sarcoma pulmonary metastases.

Department of General Thoracic Surgery, Clinica Universidad Navarra, Avenida Pio XII 36, Pamplona 31008, Spain.
Interactive Cardiovascular and Thoracic Surgery (Impact Factor: 1.11). 06/2009; 9(2):223-6. DOI: 10.1510/icvts.2009.204818
Source: PubMed

ABSTRACT Isolated pulmonary metastases from soft tissue sarcomas (STS) occur in approximately 20% of the cases. Chemotherapy and surgical resection are the current standard treatment options for these patients. Our goal was to identify any prognostic factors for these patients as well as to estimate their long-term survival rate. We examined a series of twenty-two consecutive patients with pulmonary metastases from STS, treated in our institution from 1996 to 2006. Univariate (log-rank and Cox-regression) analysis was performed to identify any significant prognostic factor. Five-year survival rates were estimated by using Kaplan-Meier methods. Four patients (18.2%) were alive without any disease, twelve patients (54.5%) died of disease and we lost all track of six patients (27.3%). Follow-up period ranged from 7 to 75 months. Median follow-up: 14 months, median survival: 19 months. Disease-free interval (DFI) (P=0.005), number of lung nodules (P=0.04) and histology type (P=0.01) were significant prognostic factors at univariate analysis. The overall five-year survival rate was 23.1%. DFI, number of lung nodules at surgery and metastatic histology are significant prognostic factors for patients with resected pulmonary metastases from STS.

Download full-text

Full-text

Available from: Salvador Martín-Algarra, Jul 04, 2015
1 Follower
 · 
159 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES Pulmonary metastasectomy for sarcoma is a widely accepted practice. Nevertheless, no previous studies has been reported the outcomes following metastasectomy compared with chemotherapy for patients with resectable and isolated pulmonary metastases. Our aim is to compare these modalities for the subset of patients with resectable metastases. Furthermore, the outcomes for patients with unresectable lung metastases are reported.METHODS Sarcoma patients with isolated lung metastases were identified and their computed axial tomography scans were reviewed by a thoracic surgeons' committee. Patients were divided into three groups: A: patients with resectable metastases treated with metastasectomy (n = 29), B: patients with resectable metastases who received systemic therapy (n = 17) and C: patients with unresectable metastases (n = 25). Survival outcomes were plotted and compared through log-rank test for osteosarcoma and non-osteosarcoma patients.RESULTSSeventy-one patients (32 with osteosarcoma and 39 with non-osteosarcoma) were eligible. Progression-free survival (PFS) was superior in patients who belonged to Group A compared with Groups B and C (8.0, 4.3 and 2.2 months, respectively, P = 0.0002). Furthermore, overall survival (OS) was superior in patients who belonged to Group A compared with Groups B and C (39.6, 20.0 and 7.8 months, respectively, P < 0.0001). A subanalysis for osteosarcoma patients showed superior PFS and OS for Group A vs B (median PFS 21.6 and 3.65 months, respectively, P = 0.011 and median OS 34.0 and 12.4 months, respectively, P = 0.0044). For non-osteosarcoma patients, there were no such significant survival differences between Groups A and B. Overall, patients who belonged to Group A had significantly lower mean percentage of their follow-up time spent admitted at hospital, and a trend towards lower requirements for home oxygen therapy.CONCLUSION Pulmonary metastasectomy is associated with improved survival of osteosarcoma patients with resectable lung metastases. For non-osteosarcoma patients, the survival benefit of metastasectomy over chemotherapy is uncertain and warrants further evaluation. Patients with unresectable metastases have poor prognosis.
    Interactive Cardiovascular and Thoracic Surgery 04/2013; DOI:10.1093/icvts/ivt177
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: Soft tissue sarcomas (STS) are a rare group of tumors with mesenchymal origin. They account for about 1% of all malignancies in adults. Due to the rareness of this tumor group, randomized clinical trials are scarce and there is little evidence concerning treatment options. METHODS: Clinical trials, published to date and literature were reviewed and edited. RESULTS: Possible different treatment approaches reflecting the present standard of care are presented and discussed. CONCLUSIONS: A multidisciplinary therapy approach and more randomized clinical trials are mandatory to improve the care for patients with STS. GRUNDLAGEN: Weichteilsarkome (WTS) sind eine Gruppe seltener Tumore mesenchymalen Ursprungs und bilden rund 1 % aller Neoplasien bei Erwachsenen. Aufgrund ihrer Seltenheit sind bisher nur sehr wenig randomisierte Studien durchgeführt worden und daher gibt es sehr wenig Evidenz für Behandlungsoptionen. METHODIK: Die klinischen Studien und gesamte rezente Literatur zu diesem Thema wurde gesichtet und aufgearbeitet. ERGEBNISSE: Verschiedene mögliche Behandlungsoptionen und Strategien, die den derzeitigen Therapiestandard reflektieren, werden präsentiert und diskutiert. SCHLUSSFOLGERUNGEN: Eine interdisziplinärer Therapieplanung und mehr randomisierte klinische Studien sind zur Verbesserung der Behandlung von Patienten mit WTS erforderlich.
    European Surgery 08/2009; 41(4):170-175. DOI:10.1007/s10353-009-0480-y
  • Current problems in cancer 03/2013; 37(2):74-86. DOI:10.1016/j.currproblcancer.2013.03.003